Fig. 3From: Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United StatesTotal irAE cases and serious irAE cases for seven FDA-approved ICIs among various cancer types. AÂ Total number of irAE cases for seven FDA-approved ICIs: patients with lung cancer ranked first or second for the highest number of total irAEs. B Number of serious irAEs for seven FDA-approved ICIs: patients with lung cancer also ranked first or second for serious irAEsBack to article page